How Stroke Rewires the Gut-Brain Axis and Disrupts Sleep
A review links post-stroke gut dysbiosis, inflammation, and neurotransmitter imbalance to sleep disorders, and points to microbiome-targeted therapies.
Summary
Sleep problems affect roughly 36-43% of stroke survivors and slow recovery. This narrative review argues that stroke sets off a chain reaction along the brain-gut axis. Stress hormones and autonomic imbalance weaken the intestinal barrier and shift gut bacteria, with fewer Bifidobacterium and Lactobacillus and more Enterobacteriaceae. Short-chain fatty acids fall and bacterial lipopolysaccharide leaks into the blood, driving inflammation that lowers serotonin and GABA signaling and raises excitotoxic glutamate. These changes disturb the suprachiasmatic nucleus clock, melatonin rhythms, and REM and slow-wave sleep. The authors propose probiotics, prebiotics, fecal microbiota transplantation, and vagus nerve stimulation as future strategies. The evidence is mostly mechanistic and preclinical, and clinical trials are still needed.
Detailed Summary
Sleep disorders are a common but under-recognized complication of stroke. The review cites prevalence of about 41% in the acute phase, 43% in the subacute phase, and 36% in the chronic phase. These disorders include insomnia, daytime sleepiness, sleep apnea, and circadian disruption. They are linked to poorer rehabilitation, cognitive decline, depression, and recurrent stroke. The authors ask whether a microbiome-immune-neurotransmitter network helps explain why.
This is a narrative review that synthesizes human and animal studies. It is not a systematic review or a new trial. It traces a proposed pathway from stroke to sleep disruption. First, stroke activates the HPA axis and sympathetic nervous system while reducing vagal tone. Cortisol rises, tight junction proteins such as occludin and claudin-5 fall, and gut permeability and transit time worsen. Second, gut microbiota diversity drops. Beneficial SCFA-producing bacteria decline and opportunistic Enterobacteriaceae expand. Third, SCFAs decrease, which weakens regulatory T cells and IL-10/TGF-β signaling. LPS leaks into the blood, activates TLR4/NF-κB, and raises IL-6 and TNF-α. This inflammation can damage the blood-brain barrier and activate microglia.
The review then links inflammation to neurotransmitters. IL-6 and TNF-α are reported to inhibit tryptophan hydroxylase and reduce serotonin synthesis, which could disturb REM regulation. Inflamed astrocytes lose glutamate transporters (GLT-1, GLAST). Extracellular glutamate then builds up, producing excitotoxicity and weaker GABA-mediated inhibition. Microbial GABA and histamine, SCFAs, and serotonin precursors also signal through the vagus nerve to the solitary nucleus and the suprachiasmatic nucleus (SCN), the body's master clock. Impaired vagal signaling, neuroinflammation, and high cortisol (which suppresses melatonin) can all disturb SCN rhythms. The result is reduced REM sleep and fragmented slow-wave sleep. The authors describe self-reinforcing loops in which poor sleep and dysbiosis worsen each other.
The authors suggest that restoring brain-gut homeostasis with probiotics, prebiotics, fecal microbiota transplantation, vagus nerve stimulation, and HPA axis modulation could improve sleep and neurological recovery. They also call for multi-omics and neural circuit studies to map how the network changes over time.
Several caveats apply. Much of the causal evidence comes from animal models such as MCAO rats and stress paradigms. Human data are largely associative. Serotonin effects differ by lesion location, for example pontine injury may raise serotonin and cause insomnia. No intervention trials in post-stroke sleep are presented, so the therapeutic proposals are hypotheses.
Key Findings
- Post-stroke sleep disorders affect about 41% of patients acutely, 43% subacutely, and 36% chronically, and are tied to worse recovery and recurrence.
- Stroke-induced HPA and sympathetic activation weaken the gut barrier and shift microbiota: fewer Bifidobacterium and Lactobacillus, more Enterobacteriaceae.
- Lower SCFAs and LPS leakage drive TLR4/NF-κB inflammation (IL-6, TNF-α), impairing regulatory T cells and the blood-brain barrier.
- Inflammation may reduce serotonin synthesis and astrocytic glutamate clearance, producing excitotoxicity and weaker GABA inhibition that disrupt REM and slow-wave sleep.
- Impaired vagal signaling and high cortisol can disturb SCN circadian control and melatonin, so vagus stimulation, probiotics, and FMT are proposed targets.
Methodology
Narrative review that synthesizes clinical and preclinical literature on the microbiome-immune-neurotransmitter network after stroke. It has no stated systematic search strategy, inclusion criteria, or quality assessment. Mechanistic claims draw on animal models (MCAO, restraint stress) and human observational studies.
Study Limitations
As a narrative review, it may be subject to selection bias, and much of the causal evidence comes from animal studies that may not translate to humans. Human evidence is mostly correlational, and findings such as serotonin effects are inconsistent across lesion sites. The review does not report interventional trials showing that microbiome modulation improves post-stroke sleep.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: